Hercules Capital HTGY 深 沪

MoonLake Immunotherapeutics GAAP EPS of -$0.84

MoonLake Immunotherapeutics press release (MLTX): Q2 GAAP EPS of -$0.84. MoonLake ended the second quarter with $537.0 million in cash, cash equivalents and short-term marketable debt securities and e...

08-10 19:12

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

08-10 11:00

Ladenburg Thalmann Maintains Buy on Hercules Capital, Lowers Price Target to $20

Ladenburg Thalmann analyst Christopher Nolan maintains Hercules Capital (NYSE:HTGC) with a Buy and lowers the price target from $21 to $20.

08-01 03:12

Hercules Capital declares $0.40 dividend

Hercules Capital (HTGC) declares $0.40/share base quarterly and $0.07 supplemental dividend, in line with previous. Forward yield 11.69% Payable Aug. 18; for shareholders of record Aug. 11; ex-div Aug...

07-28 23:34

Hercules Capital prices $325M notes offering

Hercules Capital (HTGC) priced an underwritten public offering of $325M in 6.300% notes due July 2031. The offering is expected to close on July 24, 2026. The unsecured notes will pay 6.300% annual in...

07-22 04:27

Hercules Capital updates Form 8-K regulatory disclosure

Hercules Capital, Inc. ( ($HTGC) ) has issued an announcement. In a brief regul...

07-21 20:57

Why Investors Pay Premiums for Some Private Credit Lenders — And Deep Discounts for Others

As private credit has grown into a roughly $1.8 trillion asset class, one question has become increasingly difficult for investors to answer: which lenders are actually outperforming, and which are simply benefiting from an opaque market? Publicly traded business development companies (BDCs) offer o...

07-15 00:55

Alector Ends GSK Collaboration, Retires Hercules Capital Debt

Alector ( ($ALEC) ) has provided an announcement. On October 21, 2025, Alector ...

07-09 04:32

4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital

4D Molecular Therapeutics (4DMT) has secured a $200 million strategic credit facility with Hercules Capital to support its gene therapy pipeline, particularly the Phase 3 development of 4D-150 for wet AMD and DME. The company's CFO, Kristian Humer, highlighted the agreement's benefits, including enhanced financial flexibility and a diversified capital structure. Hercules Capital expressed confidence in 4DMT's innovative approach to genetic medici...

06-29 12:00